Natalie Kingston (MSTP in PhD training)

  • Boston, MA

  • Carleton College (2016)

  • Immunology

  • David G. DeNardo, Ph.D.

  • Dual MEK and FAK inhibition in lung adenocarcinoma



Despite the immunotherapy revolution, lung cancer is still the leading cause of cancer death worldwide. KRAS mutated non-small cell lung cancer (the most common type of lung cancer) has been historically difficult to target and a large portion of patients have inherent or acquired resistance to immune checkpoint blockade therapies such as anti-PDL1. Both MAPK signaling, such as the Raf/Ras/Mek/Erk pathway, and Fak signaling have been shown to be important for the maintenance of KRAS driven NSCLC cells. Thus, we are investigating the synergistic effects of dual Mek inhibition and Fak inhibition on KRAS driven NSCLC cells in vitro and in vivo. As these therapies also affect the surrounding tumor microenvironment, we hypothesize that in addition to targeting tumor cells directly, this combination may also increase the efficacy of immunotherapy.

Graduate Publications:

Warren JT, Cupo RR, Wattanasirakul P, Spencer D, Locke AE, Makaryan V, Bolyard AA, Kelley ML, Kingston NL, Shorter J, Bellanné-Chantelot C, Donadieu J, Dale DC, Link DC. 2021 Heterozygous Variants of CLPB are a Cause of Severe Congenital Neutropenia. Blood, (epub ahead of print):.

Last Updated: 9/17/2019 8:47:27 PM

Back To Top

Follow us: